EGFR and breast carcinoma: When applied to transcriptome data from breast cancer patients, the eCOT identified EGFR/ERBB2 and multiple EGFR-related downstream targets as enriched in estrogen-receptor positive (ER+) breast cancers likely to recur late (≥ 5 years after initial diagnosis).